Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview And Scope:
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size was estimated at USD 2292.9 million in 2022 and is projected to reach USD 2079.37 million by 2028, exhibiting a CAGR of -1.62% during the forecast period.
The Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, GSK, Helsinn, Southwest Pharma, Haisco, Sun Pharma
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segmentation
By Type, Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market has been segmented into:5-HT3 Inhibitors
NK1 Inhibitors
Others
By Application, Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market has been segmented into:
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market.
Top Key Players Covered in Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market are:
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Objective to buy this Report:
1. Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market by Type
5.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview Snapshot and Growth Engine
5.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview
5.3 5-HT3 Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 5-HT3 Inhibitors: Geographic Segmentation
5.4 NK1 Inhibitors
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 NK1 Inhibitors: Geographic Segmentation
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation
Chapter 6: Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market by Application
6.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview Snapshot and Growth Engine
6.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview
6.3 Acute CINV
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Acute CINV: Geographic Segmentation
6.4 Delayed CINV
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Delayed CINV: Geographic Segmentation
6.5 Breakthrough CINV
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Breakthrough CINV: Geographic Segmentation
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 HERON THERAPEUTICS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 MERCK
7.4 EISAI
7.5 MUNDIPHARMA
7.6 QILU PHARMA
7.7 TEVA
7.8 NOVARTIS
7.9 ROCHE
7.10 MYLAN
7.11 BAXTER
7.12 GSK
7.13 HELSINN
7.14 SOUTHWEST PHARMA
7.15 HAISCO
7.16 SUN PHARMA
Chapter 8: Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 5-HT3 Inhibitors
8.2.2 NK1 Inhibitors
8.2.3 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Acute CINV
8.3.2 Delayed CINV
8.3.3 Breakthrough CINV
8.3.4 Others
Chapter 9: North America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 5-HT3 Inhibitors
9.4.2 NK1 Inhibitors
9.4.3 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Acute CINV
9.5.2 Delayed CINV
9.5.3 Breakthrough CINV
9.5.4 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 5-HT3 Inhibitors
10.4.2 NK1 Inhibitors
10.4.3 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Acute CINV
10.5.2 Delayed CINV
10.5.3 Breakthrough CINV
10.5.4 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 5-HT3 Inhibitors
11.4.2 NK1 Inhibitors
11.4.3 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Acute CINV
11.5.2 Delayed CINV
11.5.3 Breakthrough CINV
11.5.4 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 5-HT3 Inhibitors
12.4.2 NK1 Inhibitors
12.4.3 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Acute CINV
12.5.2 Delayed CINV
12.5.3 Breakthrough CINV
12.5.4 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 5-HT3 Inhibitors
13.4.2 NK1 Inhibitors
13.4.3 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Acute CINV
13.5.2 Delayed CINV
13.5.3 Breakthrough CINV
13.5.4 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 5-HT3 Inhibitors
14.4.2 NK1 Inhibitors
14.4.3 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Acute CINV
14.5.2 Delayed CINV
14.5.3 Breakthrough CINV
14.5.4 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Scope:
|
Report Data
|
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market
|
|
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size in 2025
|
USD XX million
|
|
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs CAGR 2025 - 2032
|
XX%
|
|
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Base Year
|
2024
|
|
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, GSK, Helsinn, Southwest Pharma, Haisco, Sun Pharma.
|
|
Key Segments
|
By Type
5-HT3 Inhibitors
NK1 Inhibitors
Others
By Applications
Acute CINV
Delayed CINV
Breakthrough CINV
Others
|
